A Multicenter, International, Randomized, Placebo Controlled, Double-Blind, Parallel Group And Event Driven Phase 3 Study Of The Oral Fxia Inhibitor Asundexian (BAY 2433334) For The Prevention Of Ischemic Stroke In Male And Female Participants Aged 1

Protocol No

NEURO-BAYER-OCEANIC-STROKE

Staff Member

Anne Helms

Phase

III

Summary

This project is being done to investigate the efficacy of the oral FXIa inhibitor, asundexian in prevention of ischemic stroke and its safety (bleeding) compared with placebo on top of background antiplatelet therapy in adult participants after an acute non-cardioembolic ischemic stroke or high-risk TIA.

Objective

A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled to the Brain, or Temporary Stroke-like Symptoms

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL